Palatin Technologies, Inc.

AMEX:PTN

Biotechnology

Healthcare
$9.09 -0.82%

-$0.10 today

Market cap
$236.39M
Beta
0.94
P/E (TTM)
-1.9
EPS (TTM)
-$6.43
52W Low $5.00High $31.00

Volume 0.02M

Average 1.78M

PTN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Palatin Technologies, Inc.AMEX: PTN

Stock-Based Compensation · Q3 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $419.97K rose 20.8% year over year, ahead of the -22.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 35.2% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.8% holds above the trailing-twelve-month pace of -22.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$419.97K+35.2% QoQ
Last fiscal yearJun 2025
$1.38M-26.2% YoY
LTMMar 2026
$1.24M-22.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.8%——
1 year-26.2%——
3-year CAGR-18.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
1.38M USD
Year-over-year change
-26.2%
4-year CAGR
-18.7%

Stock-Based Compensation vs competitors

How PTN compares with its peers on the latest reported figures

  • PTN's LTM Mar 2026 stock-based compensation of $1.24M is the smallest of the 2 companies compared; the peer median is $3.99M.
  • Its year-over-year change of -22.2% is the highest of 2, against a peer median of -24.8%.
  • Stock-based compensation amounts to 9.6% of revenue for PTN, versus a peer median of 7.4%.
PTN Competitors Peer median
Stock-Based Compensation for PTN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$3.99M -24.8%+61.9%7.4%
PTNPalatin Technologies, Inc.LTM Mar 2026$1.24M -22.2%-18.0%9.6%
Peer median (excluding PTN) $3.99M-24.8%+61.9%7.4%

Competitors are the stored peer set for PTN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(33.6M)(36.2M)(27.54M)(29.74M)(17.31M)
Depreciation & Amortization51.12K126.67K288.33K339.08K258.92K
Deferred Income Tax212.53K0(392.27K)00
Stock-Based Compensation3.17M2.51M1.41M1.87M1.38M
Change in Working Capital(11.9M)3.44M(2.35M)(3.41M)(758.79K)
Accounts Receivables(1.58M)(199.58K)(1.14M)2.92M(29.47K)
Inventory(987.24K)217.53K418.47K(1.15M)0
Accounts Payables(75.02K)2.57M1.11M(201.6K)2.9M
Other Working Capital(9.26M)848.81K(2.74M)(4.97M)(3.63M)
Other Non-Cash Items19.42M203.92K166.26K(530.26K)(4.88M)
Operating Cash Flow(22.65M)(29.92M)(28.42M)(31.46M)(21.31M)
Capital Expenditures(5.72K)(261.37K)(433.93K)(42.53K)(3)
Acquisitions (Net)0009.5M3.13M
Purchases of Investments00(2.99M)00
Sales of Investments0002.99M0
Other Investing Activities00000
Investing Cash Flow(5.72K)(261.37K)(3.43M)12.45M3.13M
Debt Repayment0(56.46K)(100.92K)(106.39K)(46.01K)
Common Stock Issued0010.14M14.67M7.96M
Common Stock Repurchased(93.64K)(221.31K)000
Dividends Paid00000
Other Financing Activities0296.13K(145.98K)5.99M3.3M
Financing Cash Flow(93.64K)18.36K9.9M20.55M11.21M
Effect of Forex Changes00000
Net Change in Cash(22.75M)(30.17M)(21.95M)1.54M(6.96M)
Free Cash Flow(22.65M)(30.18M)(28.85M)(31.5M)(21.31M)

Palatin Technologies, Inc.

AMEX:PTN

Intrinsic Alpha fair value

Locked

Current Price

$9.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.